dc.contributor.author | Lin, S | |
dc.contributor.author | Lian, D | |
dc.contributor.author | Liu, W | |
dc.contributor.author | Haig, A | |
dc.contributor.author | Lobb, I | |
dc.contributor.author | Hijazi, A | |
dc.contributor.author | Razvi, H | |
dc.contributor.author | Burton, J | |
dc.contributor.author | Whiteman, M | |
dc.contributor.author | Sener, A | |
dc.date.accessioned | 2018-05-22T09:56:04Z | |
dc.date.issued | 2018-03-06 | |
dc.description.abstract | OBJECTIVES: To assess the effects of slow-releasing H2S donor GYY4137 on post-obstructive renal function and injury following unilateral ureteral obstruction (UUO) by using the UUO and reimplantation (UUO-R) model in rats and to elucidate potential mechanisms by using an in vitro model of epithelial-mesenchymal transition (EMT). METHODS: Male Lewis rats underwent UUO at the left ureterovesical junction. From post-operative day (POD) 1-13, rats received daily intraperitoneal (IP) injection of phosphate buffered saline (PBS, 1 mL) or GYY4137 (200 μmol/kg/day in 1 mL PBS, IP). On POD 14, the ureter was reimplanted back into the bladder, followed by a right nephrectomy. Urine and serum samples were collected to monitor renal function. On POD 30, the left kidney was removed and tissue sections were stained with H&E, TUNEL, CD68, CD206, myeloperoxidase, and Masson's trichrome to determine cortical thickness, apoptosis, inflammation, and fibrosis. In our in vitro model of EMT, NRK52E cells were treated with 10 ng/mL TGF-β1, 10 μM GYY4137 and/or 50 μM GYY4137. Western blot analysis was performed to determine the expression of E-cadherin, vimentin, Smad7 and TGF-β1 receptor II (TβRII). RESULTS: GYY4137 led to a moderate decrease in post-obstructive serum creatinine, cystatin C and FENa. We also observed a trend towards a decrease in post-obstructive proteinuria following GYY4137 treatment. Histologically, we observed a significant decrease in apoptosis, inflammation, and fibrosis. Furthermore, our in vitro studies demonstrate that in the presence of TGF-β1, GYY4137 significantly decreases vimentin and TβRII and significantly increases E-cadherin and Smad7. CONCLUSIONS: H2S may help to accelerate the recovery of renal function post-obstruction and attenuates renal injury associated with UUO. It is possible that H2S mitigates fibrosis by regulating the TGF-β1-mediated EMT pathway. Taken together, our data suggest that H2S may be a potential novel therapy for improving renal function and limiting renal injury associated with obstructive uropathy. | en_GB |
dc.description.sponsorship | This work was supported by the Canadian Institute of Health Research. | en_GB |
dc.identifier.citation | Vol. 76, pp. 16-28. | en_GB |
dc.identifier.doi | 10.1016/j.niox.2018.03.002 | |
dc.identifier.uri | http://hdl.handle.net/10871/32958 | |
dc.language.iso | en | en_GB |
dc.publisher | Elsevier | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/29522906 | en_GB |
dc.rights.embargoreason | Under embargo until 06 March 2019 in compliance with publisher policy. | en_GB |
dc.rights | © 2018 Elsevier Inc. All rights reserved. | en_GB |
dc.subject | Epithelial mesenchymal transition | en_GB |
dc.subject | Hydrogen sulfide | en_GB |
dc.subject | Renal function | en_GB |
dc.subject | Renal injury | en_GB |
dc.subject | Transforming growth factor beta 1 | en_GB |
dc.subject | Unilateral ureteral obstruction | en_GB |
dc.title | Daily therapy with a slow-releasing H2S donor GYY4137 enables early functional recovery and ameliorates renal injury associated with urinary obstruction. | en_GB |
dc.type | Article | en_GB |
dc.identifier.issn | 1089-8603 | |
exeter.place-of-publication | United States | en_GB |
dc.description | This is the author accepted manuscript. The final version is available from Elsevier via the DOI in this record. | en_GB |
dc.identifier.journal | Nitric Oxide | en_GB |